Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA
复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

NOTICE OF 2025 FIRST EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that the 2025 first extraordinary general meeting ("**EGM**") of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") will be held at 1:30 p.m. on Thursday, 23 October 2025 at Sky Fortune Boutique Hotel Shanghai, No. 358 Hong Xu Road, Shanghai, the PRC (or any adjournment thereof) for the purposes of considering and, if thought fit, passing (with or without modifications) the following resolutions. Unless otherwise indicated, capitalised terms used herein shall have the same meanings as defined in the circular of the Company dated 29 September 2025.

SPECIAL RESOLUTIONS

1. To consider and approve the adoption of the 2025 A Share Option Scheme.

2. To consider and approve the adoption of the Management Measures for the Appraisal System of the 2025 A Share Option Scheme.

3. To consider and approve the mandate to be granted to the Board to deal with matters pertaining to the 2025 A Share Option Scheme.

4. To consider and approve the adoption of the 2025 H Share RSU Scheme.

5. To consider and approve the mandate to be granted to the Board to deal with matters pertaining to the 2025 H Share RSU Scheme.

ORDINARY RESOLUTIONS

6. To consider and approve, subject to the adoption of the 2025 H Share RSU Scheme:

   6.1 the grant of 953,500 RSUs to Mr. Chen Yuqing;

   6.2 the grant of 686,500 RSUs to Ms. Guan Xiaohui;

6.3 the grant of 686,500 RSUs to Mr. Wen Deyong;

6.4 the grant of 610,200 RSUs to Mr. Wang Kexin; and

6.5 the grant of 762,800 RSUs to Mr. Liu Yi.

7. To consider and approve the Renewed Financial Services Agreement dated 26 August 2025 entered into between the Company and Fosun Finance, the transactions contemplated thereunder and the proposed annual caps in respect of the deposit, settlement and other financial services, and to authorise the management of the Company or its authorised persons to deal with specific matters pertaining to the Renewed Financial Services Agreement.

8. To consider and approve the Renewed Products/Services Mutual Supply Framework Agreement entered into between the Company and Sinopharm on 26 August 2025 and to authorise the management of the Company or its authorised persons to deal with specific matters pertaining to the Renewed Products/Services Mutual Supply Framework Agreement.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Shanghai, the PRC

29 September 2025

As at the date of this notice, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong and Mr. Wang Kexin; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Pan Donghui and Mr. Wu Yifang; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

Notes:

1. A holder of H Shares entitled to attend and vote at the EGM is entitled to appoint one or more proxies to attend the EGM and vote by poll instead of him/her. A proxy need not be a Shareholder. If more than one proxy is so appointed, the appointment shall specify the number of H Shares in respect of which each such proxy is so appointed.

2. In order to be valid, the form of proxy together with the power of attorney or other authority (if any) under which it is signed or a certified copy thereof, must be deposited at the Company's Hong Kong share registrar for H Shares, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong no later than 24 hours before the time appointed for the convening of the EGM. Return of the form of proxy will not preclude any holder of H Shares from attending the EGM and voting in person if such shareholder so wishes and in such event, the form of proxy will be deemed to be revoked.

3. For the purpose of determining the entitlement of Shareholders to attend and vote at the EGM, the register of holders of H Shares will be closed from Monday, 20 October 2025 to Thursday, 23 October 2025 (both days inclusive). In order to qualify for attending and voting at the EGM, unregistered holders of H Shares should ensure that all transfer documents for H Shares together with the relevant Share certificates should be lodged for registration with the Company's Hong Kong share registrar for H Shares, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong no later than 4:30 p.m. on Friday, 17 October 2025.

4. Shareholders who attend the EGM in person or by proxy shall bear their own travelling and accommodation expenses.

5. This Notice of EGM is dispatched to the holders of H Shares only. The notice of EGM to the holders of A Shares and proxy form are separately published on the websites of the Company (https://www.fosunpharma.com) and the Shanghai Stock Exchange (https://www.sse.com.cn).

* *for identification purposes only*